|
|
 Previous Article | Table of Contents | Next Article 
In vitro and in vivo antileukemic activity of B43-pokeweed antiviral
protein against radiation-resistant human B-cell precursor leukemia cells
KG Waddick, DE Myers, R Gunther, LM Chelstrom, M Chandan-Langlie, JD Irvin, N Tumer and FM Uckun
Department of Therapeutic Radiology-Radiation Oncology, University of
Minnesota Health Sciences Center, Minneapolis 55113, USA.
B-cell precursor (BCP) leukemia is the most common form of childhood cancer
and represents one of the most radiation-resistant forms of human
malignancy. In this study, we examined the antileukemic efficacy of the B43
(anti-CD19)-pokeweed antiviral protein (B43-PAP) immunotoxin against
radiation-resistant BCP leukemia cells. B43-PAP caused apoptosis of
radiation-resistant primary BCP leukemia cells, killed greater than 99% of
radiation-resistant primary leukemic progenitor cells from BCP leukemia
patients, and conferred extended survival to severe combined
immunodeficiency (SCID) mice xenografted with radiation- resistant human
BCP leukemia. Furthermore, the combination of B43-PAP and total body
irradiation (TBI) was more effective than TBI alone in two SCID mouse bone
marrow transplantation models of radiation- resistant human BCP leukemia.
Thus, B43-PAP may prove useful in the treatment of radiation-resistant BCP
leukemia.
Volume 86,
Issue 11,
pp. 4228-4233,
12/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Qi, T. M. Nett, M. C. Allen, X. Sha, G. S. Harrison, B. A. Frederick, E. D. Crawford, and L. M. Glode
Binding and Cytotoxicity of Conjugated and Recombinant Fusion Proteins Targeted to the Gonadotropin-Releasing Hormone Receptor
Cancer Res.,
March 15, 2004;
64(6):
2090 - 2095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. N. Cooper, M. S. Topp, L. M. Serrano, S. Gonzalez, W.-C. Chang, A. Naranjo, C. Wright, L. Popplewell, A. Raubitschek, S. J. Forman, et al.
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect
Blood,
February 15, 2003;
101(4):
1637 - 1644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Houghton, P. C. Adamson, S. Blaney, H. A. Fine, R. Gorlick, M. Haber, L. Helman, S. Hirschfeld, M. G. Hollingshead, M. A. Israel, et al.
Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary
Clin. Cancer Res.,
December 1, 2002;
8(12):
3646 - 3657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. D. Kravtsov, J. P. Greer, J. A. Whitlock, and M. J. Koury
Use of the Microculture Kinetic Assay of Apoptosis to Determine Chemosensitivities of Leukemias
Blood,
August 1, 1998;
92(3):
968 - 980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Legrand, I. Khazaal, M. Peuchmaur, O. Fenneteau, H. Cave, P. Rohrlich, E. Vilmer, and B. Peault
Long-Term Malignant Hematopoiesis in Human Acute Leukemia Bone Marrow Biopsies Implanted in Severe Combined Immunodeficiency Mice
Blood,
September 1, 1997;
90(5):
2001 - 2009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
